Irish Heart Foundation Assumes Support for Thrombosis Patients

In a significant development for patients suffering from blood clotting disorders, the Irish Heart Foundation has announced its commitment to provide support services for those affected by thrombosis. This initiative comes in the wake of the recent cessation of operations by Thrombosis Ireland, a charity dedicated to raising awareness and providing resources about blood clotting conditions. The announcement was made on July 4, 2025, and is aimed at filling the gap left by the previous organization.

Thrombosis Ireland had been instrumental in offering information, patient stories, and resources through its website and social media channels. However, following its closure, the Irish Heart Foundation has stepped in to ensure that patients continue to receive the necessary support and information regarding thrombosis, which includes conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Emma Balmaine, the Chief Executive of the Irish Heart Foundation, emphasized the organization's dedication to preventing conditions that pose significant risks of death and disability.

According to a 2022 report from the World Health Organization (WHO), venous thrombosis is a prevalent condition affecting approximately one to two individuals per 1,000 annually in Western populations. The report further notes that DVT constitutes about two-thirds of these cases, while PE accounts for one-third, making it the third most common cardiovascular disease after myocardial infarction and stroke.

"Heart disease and stroke devastate people across Ireland, and we are committed to helping raise awareness to prevent conditions like thrombosis that increase the risk of death or disability," said Balmaine. She stressed the importance of providing comprehensive support and information to those living with thrombosis.

As part of this initiative, Ann-Marie O’Neill, the founder of Thrombosis Ireland, will join the newly established Irish Heart Foundation Council on Thrombosis in a voluntary advisory capacity. O’Neill expressed her satisfaction with the transition, stating, "As a patient who experienced thrombosis, I know firsthand how easily it can be dismissed and the challenges that can arise from the condition. I am delighted that thrombosis patients now have access to information and supports provided by the Irish Heart Foundation to support them on their health journey."

The symptoms of thrombosis can vary depending on the location and size of the blood clot. Common symptoms include swelling or pain in the legs or arms, warmth or redness in the affected area, shortness of breath, chest pain, and in severe cases, coughing up blood or experiencing persistent headaches. According to the Irish Health Service Executive, approximately 4,000 deaths annually in Ireland are attributed to thrombosis-related complications.

The Irish Heart Foundation's move to include thrombosis in its portfolio of supported cardiac conditions aligns with its overarching mission to eliminate preventable deaths from heart disease and stroke. Their commitment reflects a growing recognition of the need for targeted support for patients with thrombosis and related conditions, particularly as healthcare challenges mount in the wake of changing demographics and rising incidence rates of cardiovascular diseases.

As the landscape of healthcare in Ireland evolves, the Irish Heart Foundation’s proactive approach may pave the way for enhanced patient care and improved outcomes for those affected by thrombosis. The organization’s initiative not only aims to raise awareness but also seeks to foster a supportive community for patients navigating the complexities of living with blood clots. The future of thrombosis care in Ireland appears promising as more resources become available to support patients and their families.